Dr Reddy's to launch generic semaglutide in India

Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic and Wegovy, addressing the growing demand for accessible treatments in India.

The launch of Obeda is a significant step for Dr. Reddy’s Laboratories, as it aims to make essential medicines more affordable for patients. With diabetes and obesity rates on the rise in India, the availability of a competitively priced generic semaglutide could have a transformative impact on public health. Obeda will be offered in both injectable and oral formulations, catering to the diverse needs of patients and providing greater flexibility in treatment options.

Dr Reddy’s has ensured that Obeda meets rigorous regulatory standards, with the company confident in its ability to deliver the same therapeutic benefits as the original semaglutide formulations. This commitment to quality and efficacy underscores the company’s dedication to improving patient outcomes while maintaining affordability.

The timing of Obeda’s launch is strategic, as the global market for diabetes and weight management treatments continues to expand. Semaglutide has become a blockbuster drug, with demand surging worldwide due to its proven effectiveness in managing blood sugar levels and promoting weight loss. By entering this market with a generic alternative, Dr Reddy’s is poised to strengthen its position in the pharmaceutical industry and contribute to increased competition, which could drive down prices and improve accessibility for patients.

As the March debut approaches, industry observers are closely monitoring the potential impact of Obeda on market dynamics in India and beyond. The introduction of a generic semaglutide is expected to be a game-changer, offering hope to millions of patients who have struggled to afford branded treatments. Dr Reddy’s Laboratories continues to demonstrate its commitment to innovation and patient-centric solutions, and the launch of Obeda is yet another example of its efforts to make high-quality healthcare more accessible to all.

Source: Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say [Accessed February 25, 2026] https://www.reuters.com./world/indian-drugmaker-dr-reddys-gearing-up-march-debut-generic-semaglutide-obeda-2026-02-25/